Recent studies have centered on the overlap of GLP|glucose-dependent insulinotropic polypeptide|glucagon receptor activator therapies and dopaminergic neurotransmission. While GCGR stimulators are commonly employed for treating type 2 diabetes, their emerging impacts on motivation circuits, specifically mediated by dopaminergic networks, are gainin